AMENDMENTS TO THE CLAIMS

After entering the Substitute Specification, please amend claims 1, 6-8, 11 and 15, as provided in the following listing of claims, which will replace all prior versions and listings of claims in the application.

- 1 (currently amended). A method to produce one or more cDNA molecules comprising:
 - (a) contacting a sample comprising an mRNA templates template with a solid medium, wherein the solid medium comprises:
 - (i) -a matrix; and
 - (ii) a composition for inhibiting degradation of the mRNA template, wherein the composition is sorbed to the matrix;
 - (b) sorbing at least a portion of the mRNA template to the solid medium; and
 - (c) contacting the template with one or more reverse transcriptases under conditions sufficient to synthesize one or more cDNA molecules complementary to all or a portion of the templates template.
- 2 (previously presented). The method of claim 1, wherein the cDNA is a cDNA library.
- 3 (previously presented). The method of claim 1, wherein the mRNA is removed from the solid medium prior to the cDNA synthesis.
- 4 (previously presented). The method of claim 1, wherein the cDNA is double-stranded.
- 5 previously presented). The method of claim 1, further comprising:
 - (d) amplifying the cDNA.
- 6 (currently amended). A method for storing an mRNA molecule, comprising:
 - (a) contacting a cell comprising an mRNA molecule to be stored with a solid medium, wherein the solid medium comprises a matrix containing a

composition for substantially-inhibiting degradation of the mRNA molecule; and

(b) drying the cell and the solid medium.

7 (currently amended). The method of claim 6, wherein the composition comprises:

- (a) a weak base;
- (b) a chelating agent; and
- (c) an anionic detergent or surfactant.

8 (currently amended). The method of claim 1, wherein the matrix contains a composition for substantially inhibiting degradation of the mRNA template, the composition comprising:

- (a) a weak base;
- (b) a chelating agent; and
- (c) an anionic detergent or surfactant.

9 (previously presented). The method of claim 8, wherein the composition further comprises uric acid or a urate salt.

10 (previously presented). The method of claim 1, wherein the matrix comprises a cellulose-based matrix or paper, or a micromesh of synthetic plastic material.

11 (currently amended). The method of claim 1, wherein the solid medium matrix is selected from the group consisting of nitrocellulose, cellulose, diazocellulose, carboxymethylcellulose, hydrophilic polymers, polytetra-fluoro-ethylene, fiberglass, porous ceramics, polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, agarose, agar, starch, and nylon.

12 (previously presented). The method of claim 1, wherein the sample comprising the mRNA template is selected from the group consisting of cells, viruses, viral plaques, and preparations from biological materials.

13 (previously presented). The method of claim 7, wherein the composition further comprises uric acid or a urate salt.

14 (previously presented). The method of claim 6, wherein the matrix comprises a cellulose-based matrix or paper, or a micromesh of synthetic plastic material.

15 (currently amended). The method of claim 6, wherein the solid medium matrix is selected from the group consisting of nitrocellulose, cellulose, diazocellulose, carboxymethylcellulose, hydrophilic polymers, polytetra-fluoro-ethylene, fiberglass, porous ceramics, polystyrene, polyvinylchloride, polypropylene, polyethylene, dextran, agarose, agar, starch, and nylon.

16 (previously presented). The method of claim 1, wherein the sample comprising the mRNA template is selected from the group consisting of cells, viruses, viral plaques, and preparations from biological materials.